This episode currently has no reviews.
Submit ReviewInternational markets have outperformed the U.S. in a big way this year, but will the trend continue into Q2? Where are out traders see the biggest global gains, and if they’re betting on more divergence between the markets. Plus NIH funding cuts putting drug development on the chopping block. The names feeling the impact, and what’s at stake in the pharma space.
This episode currently has no reviews.
Submit ReviewThis episode could use a review! Have anything to say about it? Share your thoughts using the button below.
Submit Review